At close: December 13 at 4:00:02 PM EST
Pre-Market: 4:07:28 AM EST
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 9 | 6 | 10 | 10 |
| Avg. Estimate | 844.11k | 595.33k | 5.36M | 3.51M |
| Low Estimate | -- | -- | 2.7M | -- |
| High Estimate | 2.17M | 2.17M | 7.08M | 8.69M |
| Year Ago Sales | 457k | 874k | 2.83M | 5.36M |
| Sales Growth (year/est) | 84.71% | -31.88% | 89.49% | -34.45% |
Earnings History
| Currency in USD | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
|---|---|---|---|---|
| EPS Est. | -1.02 | -0.44 | -0.55 | -0.6 |
| EPS Actual | -0.71 | -0.54 | -0.51 | -0.74 |
| Difference | 0.31 | -0.1 | 0.04 | -0.14 |
| Surprise % | 30.12% | -23.29% | 6.52% | -23.13% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| DNTH | -- | -- | -- | -- |
| S&P 500 | 5.00% | 12.00% | 2.10% | 12.20% |
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/11/2024 |
| Maintains | Oppenheimer: Outperform to Outperform | 11/11/2024 |
| Maintains | Raymond James: Outperform to Outperform | 11/8/2024 |
| Initiated | Oppenheimer: Outperform | 10/3/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 9/26/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/12/2024 |
Related Tickers
SYRE Spyre Therapeutics, Inc.
24.12
+0.84%
THRD Third Harmonic Bio, Inc.
11.26
+0.09%
COYA Coya Therapeutics, Inc.
5.89
+1.20%
NGNE Neurogene Inc.
23.51
+5.26%
ACRV Acrivon Therapeutics, Inc.
7.06
+0.57%
PHVS Pharvaris N.V.
18.40
-3.26%
TECX Tectonic Therapeutic, Inc.
45.33
-2.22%
AVBP ArriVent BioPharma, Inc.
26.72
+3.25%
PEPG PepGen Inc.
4.6800
-9.30%
TRML Tourmaline Bio, Inc.
21.81
-3.15%